术者改良与定制开窗装置治疗复杂主动脉病变的早期与中期耐久性
单中心回顾性队列研究纳入32例术者改良开窗腔内修复(sm-FEVAR,均为急诊)和79例定制开窗腔内修复(CMD-FEVAR,均为择期)患者,比较技术耐久性。
要点
- 12个月免于Ia型内漏率sm-FEVAR组91.7%,CMD-FEVAR组97.7%(P=0.69)。
- 12个月免于再干预率sm-FEVAR组91.6%,CMD-FEVAR组91.7%(P=0.90)。
核心结论
- sm-FEVAR在复杂主动脉病变急诊病例中提供良好的技术成功率和中期临床结局,其耐久性可接受且与CMD-FEVAR相当,再干预率相对较低。
主要发现
- sm-FEVAR组平均随访16.3±13个月,CMD-FEVAR组20±17.3个月(P=0.28)。
- 12个月免于Ia型内漏率sm-FEVAR组91.7%(标准误5.7%),CMD-FEVAR组97.7%(标准误2.2%)(P=0.69);CMD-FEVAR组24个月为92.3%(标准误4.3%)。
- sm-FEVAR组12和24个月免于III型内漏率分别为95.5%(标准误4.4%)和88%(标准误8.2%),CMD-FEVAR组分别为92.1%(标准误3.8%)和89.2%(标准误4.7%)(P=0.68)。
- sm-FEVAR组12和24个月免于再干预率分别为91.6%(标准误5.7%)和84.6%(标准误8.6%),CMD-FEVAR组分别为91.7%(标准误4%)和83.4%(标准误5.9%)(P=0.90)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fenestrated endovascular aneurysm repair (F-EVAR) has allowed successful treatment of patients with complex aortic aneurysms. Custom-made devices (CMDs) are manufactured by companies and tailored to the patient's anatomy to incorporate target vessels, while there is also the "off label" alternative with the devices modified by a surgeon in the operating room: surgeon-modified FEVAR (sm-FEVAR). This study aims to present and compare technical durability of CMDs- and sm-FEVAR for complex abdominal and thoracoabdominal aortic pathologies. METHODS: A retrospective cohort study was undertaken including all consecutive patients treated with sm- or CMD-FEVAR during a 3-year period in a single center. Only cases with at least 3 reno-visceral target vessels were included. Primary outcomes were technical success, and freedom from endoleak (EL) (Ia or III; all branch related) and re-intervention during follow-up period. Mortality and morbidity were also recorded. RESULTS: Thirty-two sm-FEVAR patients (81,3% male) and 79 CMD-FEVAR patients (77,2% male) were included. Indication for sm-FEVAR was exclusively urgent, while all CMD- FEVAR were elective. Technical success was similar in sm-FEVAR (100%) and CMD-FEVAR (98,7%) (P = 0.523). Mean follow-up was 16.3 ± 13 and 20 ± 17.3 months for sm-FEVAR and CMD- FEVAR, respectively (P = 0.28). The freedom from EL Ia rate was 91.7% [standard error (SE) 5.7%] at 12 months in sm-FEVAR, while it was 97.7% (SE 2.2%) and 92.3% (SE 4.3%) at 12 and 24 months, respectively in CMD-FEVAR (P = 0.69). The freedom from EL III rate was 95.5% (SE 4.4%) and 88% (SE 8.2%) at 12 and 24 months, respectively in sm-FEVAR, while it was 92.1% (SE 3.8%) and 89.2% (SE 4.7%) at 12 and 24 months, respectively in CMD-FEVAR (P = 0.68). The freedom from re-intervention rate was 91.6% (SE 5.7%) and 84.6% (SE 8.6%) at 12 and 24 months, respectively in sm-FEVAR, while it was 91.7% (SE 4%) and 83.4% (SE 5.9%) at 12 and 24 months, respectively in CMD-FEVAR (P = 0.90). The survival rate was 87.5% (5.8%) and 76.3% (7.9%) at 1 and 12 months, respectively in sm-FEVAR, while it was 93.7% (2.7%) at 1 month in CMD-FEVAR without any other death during FU period. No bridging stent occlusions were noted during follow-up period in any patient. CONCLUSION: Sm-FEVAR offers good technical success and mid-term clinical outcomes in urgent cases of complex aortic pathologies. Its durability is acceptable and comparable to CMD-FEVAR with a relatively low re-intervention rate.
引用
- Spanos K, Kölbel T, Heidemann F, et al. Early and Mid-Term Durability of Surgeon-Modified and Custom-Made Fenestrated Devices for the Treatment of Complex Aortic Pathology. Ann Vasc Surg. 2021. PMID: 34954035. doi:10.1016/j.avsg.2021.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。